Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Summit Therapeutics (SMMT) Net Margin: 2016-2024

Historic Net Margin for Summit Therapeutics (SMMT) over the last 3 years, with Dec 2024 value amounting to 729,144.44%.

  • Summit Therapeutics' Net Margin was N/A to 729,144.44% in Q4 2024 from the same period last year, while for Dec 2024 it was 2,108.65%, marking a year-over-year change of. This contributed to the annual value of 2,701.87% for FY2024, which is 127568.00% down from last year.
  • Summit Therapeutics' Net Margin amounted to 729,144.44% in Q4 2024, which was up 29,314.13% from 2,478.89% recorded in Q3 2024.
  • Summit Therapeutics' 5-year Net Margin high stood at 729,144.44% for Q4 2024, and its period low was -7,700.00% during Q3 2022.
  • Its 2-year average for Net Margin is 241,307.78%, with a median of 2,478.89% in 2024.
  • Data for Summit Therapeutics' Net Margin shows a maximum YoY tumbled of 394,131bps (in 2020) over the last 5 years.
  • Over the past 3 years, Summit Therapeutics' Net Margin (Quarterly) stood at -2,296.25% in 2020, then followed by -7,700.00% in 2022, then followed by 729,144.44% in 2024.
  • Its Net Margin was 729,144.44% in Q4 2024, compared to 2,478.89% in Q3 2024 and -7,700.00% in Q3 2022.